Fundraising Fox
Lentitek
Edinburgh, GB · 2 known investors
Find your way into Lentitek
Sign up to see every warm intro you have to Lentitek
- Paths you didn't know you had: your email and LinkedIn already hold routes to the Lentitek team. We find them for you
- 2nd- and 3rd-degree connections: the friend-of-a-friend routes that take hours to manually find through your inbox or LinkedIn
- Answers now, not in days: momentum is everything in a raise. Skip asking around whether someone knows someone
Days of research, done the moment you sign in, with every route ranked by how warm it is.
Lentitek develops an alternative lentiviral vector production platform based on novel synthetic promoter technology, aimed at improving quality and yield in CAR-T manufacture and enabling in-vivo and armoured CAR applications. It works with advanced therapy (ATMP) asset developers through a serviced CRO license model to integrate and validate its vector solution.
Founders & leadership
AI
Adam IncheFounderHe has background in protein structure and cell biology, and held prior commercial roles in biomanufacturing before founding the company with Leif Anderson in 2019.
L
LeifCo-founder / Board member
JC
John CounsellChief Scientific OfficerJohn Counsell leads academic research at UCL in genetic engineering and therapeutic delivery, and serves as Chief Scientific Officer of Lentitek, a lentiviral vector technology company. He also advises Deep Science Ventures on synthetic biology and gene therapy startups.
Investors · 2
Companies House · registry record
View on Companies House ↗- Registered name
- LENTITEK LTD
- Company number
- SC633239
- Status
- Active
- Company type
- Private limited company
- Incorporated
- 12 Jun 2019
- Registered office
- Floor 3, 1-4 Atholl Crescent, Edinburgh, EH3 8HA
- Nature of business (SIC)
- 21100 — Manufacture of basic pharmaceutical products71200 — Technical testing and analysis72110 — Research and experimental development on biotechnology74909 — Other professional, scientific and technical activities n.e.c.
- Accounts
- last made up to 30 Jun 2025 · next due 31 Mar 2027
- Confirmation statement
- last made up to 3 Jul 2026 · next due 17 Jul 2027
Current officers · 3
- Leif Crombie Anderson — director, appointed 5 Jun 2021
- Adam Grant Inche — director, appointed 12 Jun 2019
- Michael Lesley Roberts — director, appointed 29 Jul 2024
Source: Companies House public register · retrieved 5 Aug 2026. Contains public sector information licensed under the Open Government Licence v3.0.
Frequently asked questions
- What does Lentitek do?
- Lentitek develops an alternative lentiviral vector production platform based on novel synthetic promoter technology, aimed at improving quality and yield in CAR-T manufacture and enabling in-vivo and armoured CAR applications. It works with advanced therapy (ATMP) asset developers through a serviced CRO license model to integrate and validate its vector solution.
- Who founded Lentitek?
- Lentitek was founded by Adam Inche, Leif.
- Who are Lentitek's investors?
- Lentitek's investors include Apollo Informal Investment, Equity Gap.
- Where is Lentitek headquartered?
- Lentitek is headquartered in Edinburgh, GB.